Imbruvica ibrutinib: Preliminary Phase II data

Preliminary data from 5 evaluable patients with relapsed or refractory MCL in the open-label, Australian Phase II AIM trial showed that once-daily 560 mg oral Imbruvica for 4 weeks as induction therapy led to 2 partial responses and 2 cases of stable disease. The trial has enrolled 8 of a planned 24 patients to receive Imbruvica for 4 weeks as induction therapy followed by the addition of Venclexta venetoclax escalated over 4 weeks to a target dose of 400 mg once daily. In 3 evaluable patients who completed 1 month of induction therapy and 3 months of combination therapy, 2 patients achieved a complete response and 1 patient achieved a partial response. The trial was sponsored by the Peter MacCallum Cancer Centre. Data will be presented at the American Society of Clinical Oncology meeting in Chicago. ...